腸内細菌叢の網羅的解析による肝細胞癌での抗PD-1抗体の治療効果予測因子の探索

• Project/Area Number: 19K07788
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Kurume University
• Principal Investigator: 鳥村 拓司 久留米大学, 付置研究所, 客員教授 (60197986)
• Co-Investigator(Kenkyū-buntansha): 光山 慶一 久留米大学, 医学部, 教授 (20200066) ; 岩本 英希 久留米大学, 医学部, 助教 (40529541) ; 古賀 浩徳 久留米大学, 医学部, 教授 (90268855)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Project Status: Completed (Fiscal Year 2023)
• Budget Amount: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000); Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000); Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 腸内細菌叢 / 免疫チェックポイント阻害剤 / 腫瘍免疫 / 肝細胞癌 / 抗腫瘍効果 / 血管新生抑制 / 血管新生阻害剤 / リンパ球 / ケモカイン / サイトカイン / Germ free

Outline of Research at the Start

ヒト肝細胞癌症例における腸内細菌叢と誘導されるサイトカイン、ケモカインの解析により、肝細胞癌に対する抗PD-1抗体の治療効果予測因子が同定する。さらに、Germ free マウスを用いたマウス肝癌細胞接種モデルおよびマウス発がんモデル(コリン欠乏アミノ酸食投与モデル、nSREBP-1cとCyclin D1ダブルトランスジェニックマウスモデル)を用いた検討にて、腸内細菌叢の腫瘍免疫に及ぼす影響を明らかにする。

Outline of Annual Research Achievements

基礎研究では、Hep55-1c.マウス肝癌細胞株を同系統のマウスに接種したモデルを用いた。治療開始24日目の腫瘍体積を各群間で比較した（n=5～6）。腫瘍体積は対照群で 1.562±0.28 cm3、抗PD-L1抗体+抗VEGD抗体群で 0.606±0.09 cm3、シンバイオティックス群(乳酸菌シロタ株 LcS及びビフィズス菌BY株 BbrY懸濁液)で1.173±0.35 cm3、 シンバイオティックス+抗PD-L1抗体+抗VEGF抗体群で0.339±0.14 cm3であり抗PD-L1抗体+抗VEGF抗体群で腫瘍体積が有意に低値を示した。シンバイオティクス摂取でもバイオティックス+抗PD-L1抗体+抗VEGF抗体群で腫瘍体積が有意に低値を示した。対照群とシンバイオティックス群及び抗PD-L1抗体+抗VEGF抗体群とシンバイオティックス+抗PD-L1抗体+抗VEGF抗体群では、シンバイオティックス群で腫瘍は縮小したが有意差はなかった。肝重量は各群間で有意差はなかった。腸内細菌叢はβ多様性の比較で違いが認められ、シンバイオティクスの摂取によって菌叢構成が変動したと考えられた。抗PD-L1抗体+抗VEGF抗体群で差はなかった。
臨床研究では、登録34例の平均生存期間は、13.7ヶ月であった。制御群(CR+PR;n=23)、非制御群(SD+PD;n=8)間での菌叢比較では多様性に差がなかった。菌の占有率ではAkkermansiaceae, Coriobacteriaceaeが制御群で多い傾向があり、AcidominococcaceaeとMonoglobaceaeは有意に多かった。Erysipelatoclostridiaeは非制御群で有意に多かった。Akkermansiaceaeが多い症例では優位に無増悪生存期間と全生存期間が延長していた。治療期間中に菌多様性の変化はなかった。

Research Products

• [Journal Article] Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors. Cancer Communications. (2023)
  • Author(s): Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, Koga H, Torimura T.
  • Journal Title: Cancer Communications. Volume: 43 Issue: 4 Pages: 415-434
  • DOI: 10.1002/cac2.12411
  • Peer Reviewed / Open Access
• [Journal Article] The Beneficial Impact of MAFLD on Lenvatinib Treatment in Patients with Non-viral Hepatocellular Carcinoma. (2023)
  • Author(s): Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T.
  • Journal Title: Hepatology Research. Volume: 53 Issue: 2 Pages: 104-115
  • DOI: 10.1111/hepr.13843
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching. (2023)
  • Author(s): Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, Noda Y, Nakano M, Suga H, Kuromatsu R, Torimura T, Koga H, Kawaguchi T.
  • Journal Title: International journal of molecular sciences. Volume: 24 Issue: 18 Pages: 13715-13715
  • DOI: 10.3390/ijms241813715
  • Peer Reviewed / Open Access
• [Journal Article] Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines) (2023)
  • Author(s): Hasegawa K、Takemura N、Yamashita T、Watadani T、Kaibori M、Kubo S、Shimada M、Nagano H、Hatano E、Aikata H、Iijima H、Ueshima K、Ohkawa K、Genda T、Tsuchiya K、Torimura T、Ikeda M、Furuse J、Akahane M、Kobayashi S、Sakurai H、Takeda A、Murakami T、Motosugi U、Matsuyama Y、Kudo M、Tateishi R
  • Journal Title: Hepatology Research Volume: 53 Issue: 5 Pages: 383-390
  • DOI: 10.1111/hepr.13892
  • Peer Reviewed / Open Access
• [Journal Article] Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells (2023)
  • Author(s): Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T.
  • Journal Title: Hepatol Int. Volume: 8 Issue: 3 Pages: 984-997
  • DOI: 10.1007/s12072-023-10572-3
  • Peer Reviewed / Open Access
• [Journal Article] Kurume Med J. (2023)
  • Author(s): Goto Y, Niizeki T, Fukutomi S, Shirono T, Shimose S, Iwamoto H, Kojima S, Kanno H, Uchino Y, Sasaki S, Shirahama N, Muroya D, Nomura Y, Akashi M, Nakayama G, Hirakawa Y, Sato T, Yoshitomi M, Sakai H, Hisaka T, Kakuma T, Koga H, Torimura T, Akagi Y, Okuda K.
  • Journal Title: Kurume Med J. Volume: 68 Pages: 239-245
  • Peer Reviewed / Open Access
• [Journal Article] The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function. (2022)
  • Author(s): Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, Koga H, Torimura T, Kawaguchi T, New Fp Study Group, Kurume Liver Cancer Study Group of Japan.
  • Journal Title: Cancers. Volume: 14 Issue: 19 Pages: 4873-4873
  • DOI: 10.3390/cancers14194873
• [Journal Article] Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. (2022)
  • Author(s): Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T.
  • Journal Title: Hepatology Communications. Volume: 6 Issue: 9 Pages: 2594-2604
  • DOI: 10.1002/hep4.2016
• [Journal Article] Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma. (2022)
  • Author(s): Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, Koga H, Torimura T.
  • Journal Title: Scientific Reports. Volume: 12 Issue: 1 Pages: 17018-17018
  • DOI: 10.1038/s41598-022-21528-2
• [Journal Article] "First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study " (2021)
  • Author(s): Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T
  • Journal Title: Cancer Medicine Volume: 10 Issue: 23 Pages: 8530-8541
  • DOI: 10.1002/cam4.4367
  • Peer Reviewed / Open Access
• [Journal Article] Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study (2021)
  • Author(s): Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T
  • Journal Title: Cancers Volume: 13 Issue: 1 Pages: 160-160
  • DOI: 10.3390/cancers13010160
  • Peer Reviewed / Open Access
• [Journal Article] Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma (2021)
  • Author(s): Iwamoto H, Niizeki T, Nagamatsu H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Kawaguchi A, Koga H, Torimura T,et al.
  • Journal Title: Cancers Volume: 13 Issue: 4 Pages: 646-646
  • DOI: 10.3390/cancers13040646
  • Peer Reviewed / Open Access
• [Journal Article] Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice (2021)
  • Author(s): Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T andon behalf of The Kurume Liver Cancer Study Group of Japan
  • Journal Title: Cancers Volume: 13 Issue: 11 Pages: 2786-2786
  • DOI: 10.3390/cancers13112786
  • Peer Reviewed / Open Access
• [Journal Article] Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion (2021)
  • Author(s): Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H and Torimura T
  • Journal Title: Cancers Volume: 13 Issue: 17 Pages: 4550-4550
  • DOI: 10.3390/cancers13174450
  • Peer Reviewed / Open Access
• [Journal Article] Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma (2021)
  • Author(s): Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T, Kurume Liver Cancer Study Group of Japan
  • Journal Title: ESMO Open Volume: 6 Issue: 1 Pages: 100020-100020
  • DOI: 10.1016/j.esmoop.2020.100020
  • Peer Reviewed / Open Access
• [Journal Article] Association between the Albumin-Bilirubin (ALBI) Score and Severity of Portoplumonary Hypertension (PoPH): A Data-mining Analysis (2021)
  • Author(s): Rapposelli IG, Shimose S, Okamura S, Nakano M, T
  • Journal Title: ESMO Open Volume: 6 Issue: 4 Pages: 100190-100190
  • DOI: 10.1016/j.esmoop.2021.100190
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma. (2020)
  • Author(s): 6Kawaguchi T, Yoshio S, Sakamoto Y, Hashida R, Koya S, Hirota K, Nakano D, Yamamura S, Niizeki T, Matsuse H, Torimura T.
  • Journal Title: Journal of Clinical Medicine Volume: 9 Issue: 4 Pages: 936-936
  • DOI: 10.3390/jcm9040936
  • Peer Reviewed / Open Access
• [Journal Article] Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events (2020)
  • Author(s): Iwamoto Hideki、Suzuki Hiroyuki、Shimose Shigeo、Niizeki Takashi、Nakano Masahito、Shirono Tomotake、Okamura Shusuke、Noda Yu、Kamachi Naoki、Nakamura Toru、Masuda Atsutaka、Sakaue Takahiko、Tanaka Toshimitsu、Nakano Dan、Sakai Miwa、Yamaguchi Taizo、Kuromatsu Ryoko、Koga Hironori、Torimura Takuji
  • Journal Title: Cancers Volume: 12 Issue: 4 Pages: 1010-1010
  • DOI: 10.3390/cancers12041010
  • Peer Reviewed / Open Access
• [Journal Article] Controlling Nutritional Status (CONUT) Score Is Associated With Overall Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib: A Multicenter Cohort Study (2020)
  • Author(s): Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T.
  • Journal Title: Nutrients Volume: 12 Issue: 4 Pages: 1076-1089
  • DOI: 10.3390/nu12041076
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. (2020)
  • Author(s): 14Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T.
  • Journal Title: Hepatology Communications. Volume: 4 Issue: 8 Pages: 1218-1228
  • DOI: 10.1002/hep4.1535
  • Peer Reviewed / Open Access
• [Journal Article] Indication of Suitable Transarterial Chemoembolization and Multikinase Inhibitors for Intermediate Stage Hepatocellular Carcinoma (2020)
  • Author(s): Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, Torimura T.
  • Journal Title: Oncol Lett. Volume: 19 Pages: 2667-2676
  • DOI: 10.3892/ol.2020.11399
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study (2019)
  • Author(s): Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T
  • Journal Title: Hepatol Int. Volume: 印刷中 Issue: 3 Pages: 293-301
  • DOI: 10.1007/s12072-019-09939-2
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Prognostic Impact of Transcatheter Arterial Chemoembolization (TACE) Combined With Radiofrequency Ablation in Patients With Unresectable Hepatocellular Carcinoma: Comparison With TACE Alone Using Decision-Tree Analysis After Propensity Score Matching (2019)
  • Author(s): Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T.
  • Journal Title: Hepatol Res. Volume: 49 Issue: 8 Pages: 919-928
  • DOI: 10.1111/hepr.13348
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. (2019)
  • Author(s): Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T
  • Journal Title: Cancer Med. Volume: 印刷中 Issue: 5 Pages: 2646-2653
  • DOI: 10.1002/cam4.2061
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] 諸条件下における進行肝細胞癌に対する薬物療法の最適治療を探る. (2023)
  • Author(s): 本理恵、新関 敬、鳥村拓司.
  • Organizer: JDDW 2023.
• [Presentation] 抗PD-L1抗体による肝癌細胞増殖機構の解明. (2022)
  • Author(s): 田中俊光、古賀浩徳、鈴木浩之、岩本英希、阪上尊彦、増田篤高、中村徹、秋葉 純、矢野博久、鳥村拓司.
  • Organizer: 第108回日本消化器病学会総会
• [Presentation] . 肝動注化学療法の適応～New FP 療法の CR 予測因子からの考察～. (2022)
  • Author(s): 新関 敬、古賀浩徳、鳥村拓司
  • Organizer: 第108回日本消化器病学会総会
• [Presentation] 肝細胞癌のレンバチニブ薬剤耐性における癌線維芽細胞の HGF-cMET シグナルの重要性 (2022)
  • Author(s): 岩本英希、古賀浩徳、鳥村拓司
  • Organizer: 第108回日本消化器病学会総会.
• [Presentation] アテゾリズマブ・ベバシズマブ併用療法開始早期の単球増加不良は治療効果不良を予測しうる (2022)
  • Author(s): 鈴木浩之、岩本英希、下瀬茂男、新関 敬、中野聖士、城野智毅、野田 悠、蒲池直紀、山口泰三、中村 徹、増田篤高、田中俊光、黒松亮子、古賀浩徳、鳥村拓司.
  • Organizer: 第58回日本肝癌研究会
• [Presentation] 肝動注化学療法はアテゾリズマブ＋ベバシズマブ併用療法の奏効性を高める (2022)
  • Author(s): 岩本英希、鳥村拓司
  • Organizer: 第58回日本肝癌研究会
• [Presentation] 切除不能進行肝細胞癌に対するレンバチニブの造影超音波検査による早期効果判定の有用性 (2021)
  • Author(s): 蒲池直紀、中野聖士、鳥村拓司
  • Organizer: 第57回日本肝臓学会総会
• [Presentation] Circulating IGFBP-1 provides molecular targeted agent-resistance in hepatocellular carcinoma (2021)
  • Author(s): Suzuki H, Iwamoto H, Nakamura T, Masuda A, Sakaue T, Tanaka T, Niizeki T, Okamura S, Shimose S, Shirono T, Noda Y, Kamachi N, Kuromatsu R, Koga H, Torimura T
  • Organizer: JSH International Liver Conference 2021
  • Int'l Joint Research
• [Presentation] BCLC B 肝細胞癌におけるレンバチニブ療法の post-progression survival 及び post treatmentの検討 (2021)
  • Author(s): 下瀬茂男、新関 敬、岩本英希、城野智毅、蒲池直紀、野田 悠、岡村修祐、中野聖士、黒松亮子、古賀浩徳、鳥村拓司
  • Organizer: 第57回日本肝臓学会総会
• [Presentation] 肝細胞癌に対する肝動注化学療法 New FP 療法とソラフェニブの治療成績の多施設後ろ向き比較研究 (2021)
  • Author(s): 岩本英希、古賀浩徳、鳥村拓司
  • Organizer: 第57回日本肝臓学会総会
• [Presentation] Primary Treatment with Molecular-targeted Agents for Hepatocellular carcinoma: A Propensity Score-matching Analysis (2021)
  • Author(s): Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T
  • Organizer: JSH International Liver Conference 2021
  • Int'l Joint Research
• [Presentation] 進行肝細胞癌に対するアテゾリズマブ,ベバシズマブ併用療法の安全性と有効性の評価-多施設共同研究- (2021)
  • Author(s): 下瀬茂男、岩本英希、新関 敬、城野智毅、野田 悠、岡村修祐、古賀浩徳、鳥村拓司
  • Organizer: 29th JDDW（第25回日本肝臓学会大会）
• [Presentation] 高齢者進行肝細胞癌に対するアテゾリズマブ及びベバシズマブ併用療法の使用経験 (2021)
  • Author(s): 城野智毅、新関 敬、岩本英希、下瀬茂男、野田 悠、岡村修祐、古賀浩徳、鳥村拓司
  • Organizer: 29th JDDW（第25回日本肝臓学会大会）
• [Presentation] "INITIAL EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD CLINICAL PRACTICE" (2021)
  • Author(s): Iwamoto H, Shimose S, Takashi N, Noda Y, Shirono T, Nakano M, Okamura S, Kamachi N, Suzuki H, Kuromatsu R, Koga H and Torimura T
  • Organizer: The Liver Meeting Digital Experience 2021（The 72th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)）
  • Int'l Joint Research
• [Presentation] 肝細胞癌に対する血管新生阻害剤の正常臓器血管への影響と癌血管特異的遺伝子の探索 (2020)
  • Author(s): 岩本英希、古賀浩徳、鳥村拓司
  • Organizer: 第106回日本消化器病学会総会
• [Presentation] 肝細胞癌（HCC）に対するBalloon-Occluded Transarterial Chemoembolization（B-TACE）とCoventional TACE（C-TACE）のTE4. (2020)
  • Author(s): 城野智毅、新関 敬、岩本英希、下瀬茂男、蒲池直紀、野田 悠、岡村修祐、中野聖士、黒松亮子、古賀浩徳、鳥村拓司.
  • Organizer: 第56回日本肝臓学会総会
• [Presentation] Lenvatinibは腫瘍微小環境をimmune cold からhotへと変化させる. (2020)
  • Author(s): 鈴木浩之、岩本英希、鳥村拓司
  • Organizer: 28th JDDW（第24回日本肝臓学会大会）
• [Presentation] TACE不応肝細胞癌に対するレンバチニブ療法とrepeated TACEの有効性の比較 傾向スコアを用いて. (2020)
  • Author(s): 下瀬茂男、新関 敬、岩本英希、城野智毅、岡村修祐、中野聖士、高田晃男、田中正俊、古賀浩徳、鳥村拓司.
  • Organizer: 28th JDDW（第24回日本肝臓学会大会）
• [Presentation] 造影CTにおける造影効果を含めた腫瘍因子からみたレンバチニブの治療効果について. (2020)
  • Author(s): 岡村修祐、下瀬茂男、新関 敬、蒲池直紀、野田 悠、城野智毅、岩本英希、中野聖士、黒松亮子、古賀浩徳、鳥村拓司.
  • Organizer: 28th JDDW（第24回日本肝臓学会大会）
• [Presentation] Involvement of WNT Signaling in Two-faced Actions of Claudin-2 in Liver Cancer Cells (2019)
  • Author(s): Koga H, Imamura Y, Nakamura T, Iwamoto H, Sakaue T, Masuda A, Tanaka T, Nakano D, Suzuki H, Yano H and Torimura T
  • Organizer: The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Int'l Joint Research
• [Presentation] A Comparative Study of Necrosis-inducing Effect on Hepatocellular Carcinoma: Balloon-Occluded VS. Conventional Transcatheter Arterial (2019)
  • Author(s): Shirono T, Iwamoto H, Niizeki T, Shimose S, Koga H and Torimura T
  • Organizer: The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Int'l Joint Research
• [Presentation] Real World Evidence of Lenvatinib in Adavanced Hepatocellular Carcinoma: A Multicenter Cohort Study (2019)
  • Author(s): Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H and Torimura T
  • Organizer: The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Int'l Joint Research
• [Presentation] Prognostic Indication of Transarterial Chemoembolization and Multikinase Inhibitors in Patients with Intermediate Stage Hepatocellular Carcinoma (2019)
  • Author(s): Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H and Torimura T
  • Organizer: The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Int'l Joint Research
• [Presentation] Lenvatinib Alters Tumor Immune Microenvironment from ‘COLD’ TO ‘HOT’ in Hepatocellular Carcinoma (2019)
  • Author(s): Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Masuda A, Nakamura T, Koga H and Torimura T
  • Organizer: The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • Int'l Joint Research
• [Book] 腸内細菌と肝細胞癌 (2021)
  • Author(s): 腸内細菌と肝細胞癌
  • Total Pages: 3
  • Publisher: 医学書院
• [Book] ラムシルマブによる肝細胞癌治療 (2020)
  • Author(s): 鳥村拓司、中野聖士、岩本英希
  • Total Pages: 223
  • Publisher: アークメディア
  • ISBN: 9784875832379
• [Book] 肝癌診療マニュアル (2020)
  • Author(s): 鳥村拓司、長谷川潔、泉並木、工藤正俊
  • Total Pages: 278
  • Publisher: 医学書院
  • ISBN: 9784260040815